Medical startup Medii said on April 23 that it has built a physician collaboration system with the Japanese Society of Child Neurology to support the safe and appropriate use of Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys (delandistrogene…
To read the full story
Related Article
- Elevidys Needs More Safety Data to Support Full Approval: Expert
June 18, 2026
- DMD Gene Therapy Elevidys Hits Japan Market at Record Price
February 20, 2026
BUSINESS
- CSL Behring Japan Names Edward Wright as New Chief
October 2, 2026
- Takeda Welcomes 39 Prospective 2027 Hires in Japan
October 2, 2026
- Nippon Shinyaku Reports 5-Year Efficacy Data for DMD Hopeful
October 2, 2026
- Taiho’s ASTX030 Hits PIII Goal, US Filing Planned
October 2, 2026
- Ono Moves US Venture Capital Arm to Cambridge
October 2, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…





